The FDA's recent battle with NuVision Pharmacy highlights challenges in the agency's efforts to regulate compounding pharmacies that won't obey enforcement actions, Ed Silverman writes. The FDA may use the pharmacy's refusal to carry out a recall as a reason for Congress to explicitly spell out the agency's authority to regulate compounding pharmacies, he writes.

Full Story:

Related Summaries